About our Company
A&B Biotechnologies provides a comprehensive 'biomaterial to validated data' genomics services platform, helping researchers gain the pre-clinical data for breakthroughs in drug discovery, molecular diagnostics and pharmacogenomics. Utilizing A&B Biotechnologies's genomics services platform, researchers can identify genetic markers, validate drug targets that cause disease and correlate clinical data with molecular data to accelerate the development of new and safer drugs.
With the largest collection of ready-to-use, clinically defined, pathology-validated human specimen derivatives on the market, A&B Biotechnologies facilitates biomedical research and drug discovery efforts for cancer, neurodegenerative diseases, cardiovascular diseases, diabetes / obesity and autoimmune disease research.
A&B Biotechnologies's services extend from nucleic acids
processing, DNA synthesis, high throughput sequencing and
genotyping, genome wide-scans and gene expression analyses to
ready-made large epidemiologically sound case-control studies of
inflammatory disorders, endocrine disorders, cardiovascular
disease, diabetes, hypertension, obesity and many cancers.
To facilitate high-throughput screening of human clinical
specimens, A&B Biotechnologies provides its tissue lysate
library on ready-to-use protein microarrays. And, for protein
localization, immunohistochemical and in-situ hybridization
studies, A&B Biotechnologies' tissue microarrays are an ideal
method for studying multiple human cancer / normal tissues in a
single assay.
A&B Biotechnologies's customers include leading pharmaceutical and biotechnology companies, and government and academic research institutions. A&B Biotechnologies has headquarters in Istanbul Turkey, Beltsville, MD and Hyderabad, India.